Endo proposes to buy Auxilium for $2.6bn in cash and stock; finalized
Executive Summary
Endo International PLC made an unsolicited bid to acquire publicly traded Auxilium Pharmaceuticals Inc. (focused on men’s health care) for $2.2bn equally in cash and stock, equating to $28.10 per share (a 35% premium). Auxilium’s board is reviewing the proposal, and also adopted a poison pill plan that will trigger the issuance of new Auxilium shares if an individual or group owns 15% or more in equity.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice